{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with International', 'Committee of Medical Journal Editors authorship requirements', '12.2.12. Clinical Events Committee', 'An external independent CEC blinded to treatment allocation will adjudicate all clinical', 'events reported during this study that are referred for adjudication, including major', 'adverse cardiovascular events (MACE; composite of all-cause mortality [CV and non-CV', 'mortality], non-fatal MI and non-fatal stroke) and additional components for a broader', 'definition of MACE including thromboembolic events (vascular access thrombosis,', 'symptomatic deep vein thrombosis, symptomatic pulmonary embolism), and', 'hospitalization for heart failure (Section 9.3.5).', '12.2.13. Safety Review Team (SRT)', 'An internal Safety Review Team, which includes GSK personal involved in the conduct', 'of the study, will review periodically blinded safety data from this trial.', '82']['2016N298481_02', 'CONFIDENTIAL', '205270', '12.3.', 'Appendix 3: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator (ie, not related to progression of', 'underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses should be reported regardless of sequelae.', '\"Lack of efficacy\" or \"failure of expected pharmacological action\" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy', 'assessments. However, the signs, symptoms, and/or clinical sequelae resulting from', 'lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE', 'or SAE.', 'The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be', 'reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, \"lack of', 'efficacy\" or \"failure of expected pharmacological action\" constitutes an AE or SAE.', '83']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', \"investigator to be more severe than expected for the participant's condition.\", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', \"participant's condition.\", 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable, then the site will use the paper SAE data', 'collection tool (see next section) in order to report the event within 24 hours.', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', 'The investigator or medically-qualified sub-investigator must show evidence within', 'the eCRF (e.g., check review box, signature, etc.) of review and verification of the', 'relationship of each SAE to IP/study participation (causality) within 72 hours of SAE', 'entry into the eCRF.', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section) or to the medical monitor/SAE coordinator by telephone.', 'Contacts for SAE reporting can be found at the beginning of this protocol on the', 'Medical Monitor Contact Information page.', '84']\n\n###\n\n", "completion": "END"}